Xeris Biopharma Holdings, Inc. (FRA:2B30)
Germany
· Delayed Price · Currency is EUR 5.47
-0.42 (-7.13%)
At close: Dec 3, 2025
Xeris Biopharma Holdings Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2016 |
| Net Income | -15.64 | -54.84 | -62.26 | -94.66 | -122.73 | -91.14 | Upgrade
|
| Depreciation & Amortization | 12.63 | 12.63 | 13.16 | 12.67 | 1.88 | 1.47 | Upgrade
|
| Other Amortization | 3.33 | 3.01 | 2.21 | 1.56 | 0.96 | 0.98 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.09 | 0.09 | 0.32 | 0.24 | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -0.07 | -0.75 | -1.26 | 0.18 | 0.41 | 0.08 | Upgrade
|
| Stock-Based Compensation | 20.69 | 18.36 | 10.72 | 12.16 | 11.38 | 8.27 | Upgrade
|
| Other Operating Activities | -0.01 | -6.66 | -3.61 | 0.11 | 0.7 | 2.58 | Upgrade
|
| Change in Accounts Receivable | -12.61 | -1.22 | -8.37 | -13.37 | -6.24 | -2.18 | Upgrade
|
| Change in Inventory | -18.41 | -8.78 | -14.8 | -7.47 | -7.42 | -5.14 | Upgrade
|
| Change in Accounts Payable | -3.57 | -9.61 | 6.96 | -4.32 | 5.53 | -2.49 | Upgrade
|
| Change in Other Net Operating Assets | 24.14 | 10.79 | 9.92 | -9.99 | 19.98 | 7.01 | Upgrade
|
| Operating Cash Flow | 10.56 | -36.98 | -47.02 | -102.89 | -95.54 | -80.56 | Upgrade
|
| Capital Expenditures | -0.58 | -0.87 | -2.26 | -0.52 | -1.09 | -0.38 | Upgrade
|
| Cash Acquisitions | - | - | - | - | 38.47 | - | Upgrade
|
| Investment in Securities | 10.24 | 5.75 | -3.74 | 34.99 | 60.58 | -27.03 | Upgrade
|
| Investing Cash Flow | 9.65 | 4.88 | -6 | 34.46 | 97.96 | -27.41 | Upgrade
|
| Long-Term Debt Issued | - | 50 | - | 146.21 | - | 94.84 | Upgrade
|
| Long-Term Debt Repaid | - | - | - | -43.5 | - | -25.09 | Upgrade
|
| Net Debt Issued (Repaid) | - | 50 | - | 102.72 | - | 69.75 | Upgrade
|
| Issuance of Common Stock | 21.56 | 1.73 | 0.58 | 30.84 | 27.84 | 66.7 | Upgrade
|
| Repurchase of Common Stock | -9.5 | -3.73 | -1.01 | -0.47 | -0.53 | -0.06 | Upgrade
|
| Other Financing Activities | - | -11.83 | -1.19 | -5.61 | -0.05 | -10.32 | Upgrade
|
| Financing Cash Flow | 12.05 | 36.17 | -1.61 | 127.47 | 27.25 | 126.06 | Upgrade
|
| Foreign Exchange Rate Adjustments | - | - | - | - | -0 | -0.02 | Upgrade
|
| Net Cash Flow | 32.26 | 4.07 | -54.64 | 59.04 | 29.67 | 18.08 | Upgrade
|
| Free Cash Flow | 9.98 | -37.85 | -49.29 | -103.42 | -96.62 | -80.94 | Upgrade
|
| Free Cash Flow Margin | 3.75% | -18.64% | -30.07% | -93.80% | -194.84% | -396.06% | Upgrade
|
| Free Cash Flow Per Share | 0.06 | -0.26 | -0.36 | -0.76 | -1.22 | -1.90 | Upgrade
|
| Cash Interest Paid | 26.19 | 26.95 | 27.69 | 10.86 | 7.29 | 4.56 | Upgrade
|
| Levered Free Cash Flow | 28.55 | -27.81 | -19.62 | -65.85 | -28.19 | -52.91 | Upgrade
|
| Unlevered Free Cash Flow | 43.74 | -11.76 | -5.2 | -58.6 | -24.67 | -47.22 | Upgrade
|
| Change in Working Capital | -10.46 | -8.82 | -6.29 | -35.15 | 11.85 | -2.8 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.